Products
Pre-made Regavirumab benchmark antibody (Whole mAb, anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-970
Anti-HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] therapeutic antibody (Pre-made Regavirumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-970-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-970-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-970-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-970-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Regavirumab Biosimilar, Whole Mab: Anti-Hcmv (Human Cytomegalovirus) Envelope Glycoprotein B (Gb) [Human Betaherpesvirus 5] therapeutic antibody |
| INN Name | Regavirumab |
| Target | HCMV (human cytomegalovirus) envelope glycoprotein B (gB) [Human betaherpesvirus 5] |
| Format | Whole mAb |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Teijin Ltd. (Tokyo Japan) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Human hybridoma |
<